InvestorsHub Logo
Followers 1183
Posts 134793
Boards Moderated 3
Alias Born 08/27/2003

Re: None

Tuesday, 08/25/2009 9:24:15 AM

Tuesday, August 25, 2009 9:24:15 AM

Post# of 5943
REPR -- profitable, cash-rich, rapidly growing, recession-proof, tiny float OS & market cap with a juicy FDA approval pending any week...

Management is so confident of continued much higher profits than last quarter going forward that they have set aside a "deferred tax asset" in the balance sheet "based the valuation allowance calculations on the prospect of future profitability"

Products are recession-proof with no direct competition with sales rapidly expanding due to a new treatment (Vivaglobin) where their infusion pump is the best, cheapest, safest, and most convenient form of delivery:

Medicare reimbursement for the Freedom60 (their biggest & most exciting revenue-generating product) was increased 20 fold in June of 2007 and is the ONLY infusion pump accepted by Medicare for reimbursement for Subcutaneous Immune Globulin treatment (Vivaglobin):

They are hiring like crazy:

FDA Approval pending and could be announced any day which should help accelerate sales & earnings:

Based on seasonal & cylical patterns as well as their recent hiring and doubling of shifts and landing business with a huge hospital & the pending FDA approval, I suspect REPR is 1 or 2 quarters away from +.02 EPS per quarter or more or an annualized +.08 EPS pace IMO. 10 PE = .80/share, 15 PE = $1.20/share. 20 PE = $1.80/share

REPR Board:

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.